Polylactide compositions and uses thereof
The present invention provides compositions and methods relating to polylactides which may be used for drug delivery (e.g., parenteral delivery), wherein an organic solvent is not required.
1. A pharmaceutical composition comprising a compound having the structure:
wherein R 1 , R 2 , R 3 , and R 4 are each independently chosen from the group consisting of unsubstituted C 1-20 alkyl, H, C 2-20 alkenyl, and —(CH 2 ) y —(C 6 H 5 ); wherein y=1-20;
wherein n is 2 to 100; wherein X is hydrogen or —C(O)—CH═CH 2 ;
wherein at least one of R 1 , R 2 , R 3 , and R 4 is C 4-20 unsubstituted alkyl, C 2-20 alkenyl, or —(CH 2 ) y —(C 6 H 5 );
wherein y=1-20; wherein Y is —O—(CH 2 —CH 2 —O) p —CH 3 ; and
wherein p is 1 to 700.
2. The pharmaceutical composition of claim 1 , wherein the compound is comprised in micelles.
3. The pharmaceutical composition of claim 2 , wherein the pharmaceutical composition is formulated for topical administration.
4. The pharmaceutical composition of claim 2 , wherein the pharmaceutical composition is formulated as an eye drop.
5. The pharmaceutical composition of claim 1 , wherein n is 2 to 75.
6. The pharmaceutical composition of claim 5 , wherein n is 2 to 50.
7. The pharmaceutical composition of claim 1 , wherein p is 1 to 250.
8. The pharmaceutical composition of claim 5 , wherein R 1 and R 3 are hydrogen; and R 2 and R 4 are C 4-20 alkyl.
9. The pharmaceutical composition of claim 8 , wherein R 2 and R 4 are —(CH 2 ) m —CH 3 , wherein m is from 3-19.
10. The pharmaceutical composition of claim 9 , wherein m is from 3 to 12.
11. The pharmaceutical composition of claim 1 , wherein R 1 and R 3 are hydrogen; and wherein R 2 and R 4 are —(CH 2 ) m —CH 3 or —CH 3 , wherein m=3-12.
12. The pharmaceutical composition of claim 11 , wherein m=3-9.
13. The pharmaceutical composition of claim 1 , wherein m=4-6.
14. The pharmaceutical composition of claim 1 , wherein m=5.
15. The pharmaceutical composition of claim 6 , wherein n is 2 to 25.
16. The pharmaceutical composition of claim 1 , wherein R 1 and R 3 are hydrogen; and wherein R 2 and R 4 are —(CH 2 ) m —CH 3 , wherein m=3-12.
17. The pharmaceutical composition of claim 1 , wherein R 1 and R 3 are hydrogen; and wherein R 2 and R 4 are —(CH 2 ) 5 —CH 3 or —CH 3 .
18. The pharmaceutical composition of claim 1 , wherein R 1 and R 3 are hydrogen; and wherein R 2 and R 4 are —(CH 2 ) 5 —CH 3 .
19. The pharmaceutical composition of claim 18 , wherein the compound is comprised in micelles.
20. The pharmaceutical composition of claim 19 , wherein the pharmaceutical composition is formulated for topical administration.
21. The pharmaceutical composition of claim 20 , wherein the pharmaceutical composition is formulated as an eye drop.
22. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises a hydrophobic drug.
23. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition does not comprise a hydrophobic drug.